Loading clinical trials...
Loading clinical trials...
A Phase 3, Randomized, Open-label Study to Evaluate the Efficacy and Safety of Sac-TMT (Sacituzumab Tirumotecan, MK-2870) Followed by Carboplatin/Paclitaxel vs Chemotherapy, Both in Combination With Pembrolizumab as Neoadjuvant Therapy for High-Risk, Early-Stage, Triple-Negative Breast Cancer or Hormone Receptor-low Positive/Human Epidermal Growth Factor Receptor-2 Negative Breast Cancer
Conditions
Interventions
Sacituzumab tirumotecan
Pembrolizumab
+8 more
Locations
268
United States
Banner MD Anderson Cancer Center ( Site 0066)
Gilbert, Arizona, United States
Mayo Clinic Cancer Center ( Site 0034)
Phoenix, Arizona, United States
University of Arizona Cancer Center ( Site 0035)
Tucson, Arizona, United States
Roy and Patricia Disney Family Cancer Center ( Site 0055)
Burbank, California, United States
Providence Medical Foundation ( Site 0080)
Fullerton, California, United States
Hoag Memorial Hospital Presbyterian ( Site 0010)
Newport Beach, California, United States
Start Date
June 30, 2025
Primary Completion Date
March 23, 2033
Completion Date
December 29, 2034
Last Updated
April 17, 2026
NCT06608446
NCT04389632
NCT07174336
NCT04895709
NCT05386108
NCT07191730
Lead Sponsor
Merck Sharp & Dohme LLC
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions